Quebec Recommends RSV Vaccines Including AREXVY

The Committee on Immunization of Quebec (CIQ) today recommended using RSV (respiratory syncytial virus) vaccines, including AREXVY™, to prevent RSV among older adults at increased risk of severe outcomes from the virus.

Specifically, CIQ recommends vaccination for older adults living in residential and long-term care centers, intermediate resources, adults aged 75 and older living in private seniors’ residences, and those living in the community with chronic illnesses.

The CIQ recommendations for RSV vaccination follow those issued by the National Advisory Committee on Immunization,  published earlier in July 2024.

Marni Freeman, Country Medical Director, GSK Canada, said in a press release on July 24, 2024, “As our immune system ages, we all become more vulnerable to severe consequences of RSV disease."

"Older adults who are immunocompromised or suffer from underlying medical conditions, such as chronic heart or lung disease, are at an even greater risk.

"The CIQ recommendation reflects the important role AREXVY can play in reducing the incidence and overall burden of respiratory syncytial virus among Quebec’s older adult population, and we look forward to collaborating with public health officials, healthcare professionals, and payers to ensure optimal vaccine access in the province.”

AREXVY was approved in Canada in August 2023 and is indicated for preventing lower respiratory tract disease caused by RSV in individuals 60 and older.

This vaccine (May 2023), two other RSV vaccines, and one monoclonal antibody for infants have been approved for use in the United States. 

RSV is a common, contagious virus that affects the lungs and respiratory airways. For most people, the virus causes cold-like symptoms. Still, for older adults and adults with certain health conditions, it can lead to more serious infections and complications such as pneumonia, hospitalization, and even death, says the CIQ.